The question of whether alterations in methylation are results of aging and pathology or in fact one of its contributing factors has not been decisively solved yet. A wide variety of age-associated diseases exhibit abnormal methylation and many prospective treatments based on rejuvenating the methylome are yet unexplored. Future research will require a better understanding of alleged mechanisms surrounding DNMTs and their associated partners in DNA methylation. Advanced research into methylomic aging, associated disease, drug discovery, and regulatory mechanisms is essential to uncover the function of DNA methylation in aging, rejuvenation, and age-associated disease.